BRAF/MEK抑制剂诱导对比一线伊匹木单抗/纳武利尤单抗在预后不良晚期黑色素瘤中的研究
本研究基于荷兰黑色素瘤治疗登记数据库,纳入709例BRAF突变晚期黑色素瘤患者,比较BRAF/MEK抑制剂诱导后计划转换为伊匹木单抗/纳武利尤单抗(IPI/NIVO)与一线IPI/NIVO的疗效。倾向性评分匹配队列(n=280)中,两组中位无进展生存期(PFS)和总生存期(OS)无统计学显著差异。在无症状脑转移、肝转移、LDH 250-500 U/L及≥3个转移部位亚组中,一线IPI/NIVO显示出显著更优的PFS或OS。
要点
- 匹配队列中BRAF/MEK诱导与一线IPI/NIVO的PFS和OS无显著差异。
- 无症状脑转移患者一线IPI/NIVO的PFS和OS均显著优于诱导治疗。
- 肝转移、LDH 250-500 U/L及≥3个转移部位患者一线IPI/NIVO的OS显著更优。
核心结论
- 在匹配和按预后特征分层的分析中,BRAF/MEK抑制剂诱导后转换为IPI/NIVO相比一线IPI/NIVO未显示出显著获益。
研究设计与样本
- 研究为基于荷兰黑色素瘤治疗登记数据库的回顾性队列研究,纳入2016年至2023年间接受BRAF/MEK抑制剂(<120天)后计划转换为IPI/NIVO或一线IPI/NIVO的BRAF突变晚期黑色素瘤患者。
- 共纳入709例患者,其中187例接受BRAF/MEK诱导,522例接受一线IPI/NIVO;采用倾向性评分匹配队列(n=280)进行分析。
主要发现
- 匹配队列中,BRAF/MEK诱导组中位PFS为6.5个月(95%CI 5.3-8.1),一线IPI/NIVO组为6.6个月(95%CI 4.3-11.3),差异无统计学意义。
- 匹配队列中,BRAF/MEK诱导组中位OS为20.0个月(95%CI 17.2-35.3),一线IPI/NIVO组为54.0个月(95%CI 21.7-64.4),差异无统计学意义。
- 无症状脑转移亚组中,一线IPI/NIVO组中位PFS为9.4个月(95%CI 6.3-28.2),BRAF/MEK诱导组为4.8个月(95%CI 4.1-5.3),p<0.01。
- 无症状脑转移亚组中,一线IPI/NIVO组中位OS为60.4个月(95%CI 39.1-NR),BRAF/MEK诱导组为16.2个月(95%CI 11.7-31.8),p<0.01。
- 肝转移亚组中,一线IPI/NIVO组中位OS为49.8个月(95%CI 32.1-60.3),BRAF/MEK诱导组为14.1个月(95%CI 12.1-20.5),p<0.01。
临床怎么用
- 对于BRAF突变晚期黑色素瘤患者,尤其是具有无症状脑转移、肝转移、LDH 250-500 U/L或≥3个转移部位等预后不良特征者,一线IPI/NIVO可能优于BRAF/MEK抑制剂诱导后转换策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: BRAF/MEK inhibitor induction therapy (BRAF/MEK-i) followed by ipilimumab/nivolumab (IPI/NIVO) did not show benefit over upfront IPI/NIVO in unselected advanced melanoma patients in clinical trial setting. We investigated BRAF/MEK-i in subgroups of patients with advanced melanoma and poor prognostic characteristics. METHODS: Patients with BRAF-mutant advanced melanoma treated with BRAF/MEK inhibitors (<120 days) followed by planned switch to IPI/NIVO or upfront IPI/NIVO between 2016 and 2023 were included from the nationwide Dutch Melanoma Treatment Registry. Progression-free survival (PFS) and overall survival (OS) were analyzed in propensity score-matched cohorts and subgroups (LDH 250-500 and >500U/L, symptomatic and asymptomatic brain metastases (BMs), liver metastases, ≥ 3 metastatic sites, and ECOG PS ≥ 2). RESULTS: We included 709 patients (187 BRAF/MEK-i and 522 upfront IPI/NIVO). In the matched cohort (n = 280), median PFS and OS were not statistically significantly different: 6.5 (95 %CI 5.3-8.1) and 20.0 (95 %CI 17.2-35.3) months for BRAF/MEK-i vs. 6.6 (95 %CI 4.3-11.3) and 54.0 (95 %CI 21.7-64.4) months for upfront IPI/NIVO. Upfront IPI/NIVO showed significantly improved PFS compared to BRAF/MEK-i for asymptomatic BMs (median 9.4 months (95 %CI 6.3-28.2) vs. 4.8 months (95 %CI 4.1-5.3); p < 0.01), and significantly improved OS for asymptomatic BMs (median 60.4 months (95 %CI 39.1-NR) vs. 16.2 months (95 %CI 11.7-31.8); p < 0.01), liver metastases (median 49.8 months (95 %CI 32.1-60.3) vs. 14.1 months (95 %CI 12.1-20.5); p < 0.01), LDH 250-500 U/L (median 52.7 months (95 %CI 35.1-NR) vs. 20.1 months (95 %CI 13.9-35.5); p = 0.03), and ≥ 3 metastatic sites (median 54.0 months (95 %CI 39.1-NR) vs. 16.7 months (95 %CI 13.8-24.8); p < 0.01). CONCLUSIONS: BRAF/MEK-i showed no significant benefit over upfront IPI/NIVO in matched and stratified analyses according to prognostic characteristics.
引用
- Bloem M, van den Eertwegh AJM, Haanen JBAG, et al. Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma. Eur J Cancer. 2025. PMID: 41129985. doi:10.1016/j.ejca.2025.116062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。